2289 Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

2297 The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation
Martijn P. Lolkema, Hilde H. Bohets, Hendrik-Tobias Arkenau, Ann Lampo, Erio Barale, Maja J.A. de Jonge, Leni van Doorn, Peter Helleman, Johann S. de Bono, and Ferry A.L.M. Eskens

2305 Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
Lawrence G. Lum, Archana Thakur, Zaid Al-Kadhimi, Gerald A. Colvin, Francis J. Cummings, Robert D. Legare, Don S. Dixon, Nicola Kouttab, Abby Maizel, William Colaiace, Qin Liu, and Ritesh Rathore

PERSONALIZED MEDICINE AND IMAGING

2315 Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

CANCER THERAPY: PRECLINICAL

2325 Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms
Michele Cioffi, Sara Trabulo, Manuel Hidalgo, Eithne Costello, William Greenhalf, Mert Eker, Joerg Kleeff, Bruno Sainz Jr, and Christopher Heeschen

2338 Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation
Masanori Hasegawa, Raj Kumar Sinha, Manoj Kumar, Maroof Alam, Li Yin, Deepak Raina, Akruti Kharbanda, Govind Panchamoorthy, Dikshi Gupta, Harpal Singh, Surender Kharbanda, and Donald Kufe

BIOSCIENCE

2348 Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
Matthew C. Stubbs, Wonil Kim, Megan Bariteau, Tina Davis, Siddhar Vempati, Janna Minehart, Matthew Wikkin, Jun Qi, Andrei V. Kritsov, James E. Bradner, Andrew L. Kung, and Scott A. Armstrong

BIOLOGY OF HUMAN TUMORS

2359 Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein
Murali Janakiram, Jordan M. Chinai, Susan Fineberg, András Fiser, Cristina Montagna, Ramadevi Medavarapu, Ekaterina Castano, Hyungjuin Jeon, Kim C. Ohakebulam, Ruihua Zhao, Aimin Zhao, Steven C. Almo, Joseph A. Sparano, and Xingxing Zang
See related commentary, p. 2201

2367 Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System
See related commentary, p. 2204

2379 Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non–Small Cell Lung Cancer
Ahnah Song, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Bhumsuk Keam, Se-Hoon Lee, and Dae Seog Heo

2388 Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
Jasmin Wellbrock, Emily Latuske, Julian Köhler, Katharina Wagner, Hauke Stamm, Ek Vettorazzi, Gabi Vohwinkel, Mariannne Klokow, Roswitha Ubileisen, Patrick Ehms, Kristoffer Riecken, Sonja Loges, Felicitas Thol, Claudia Schubert, Michael Amling, Manfred Jäcker, Carsten Bokemeyer, Michael Heuser, Jürgen Krauter, and Walter Fiedler

CORRECTION

2399 miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma
Yijun Yang, Fei Li, Manujendra N. Saha, Jahangir Abdi, Lugui Qiu, and Hong Chang

2412 Correction: Ceritinib for the Treatment of Late-Stage (Metastatic) Non–Small Cell Lung Cancer

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org
ABOUT THE COVER

The cover shows a section of a bone marrow biopsy from a patient with acute myeloid leukemia (AML). Immunohistochemical staining shows Desert Hedgehog positive osteoblasts underlining the hypothesis of paracrine Hedgehog pathway activation in AML cells. For details, see the article by Wellbrock and colleagues on page 2388 of this issue.